Tatyana Dronova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tatyana Dronova has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Natalia N. Babyshkina
Department of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk - Russian Federation and Siberian State Medical University, Tomsk - Russian Federation
16 shared publications - Nadezhda V. Cherdyntseva
Cancer Research Institute, Tomsk National Research Medical Center, 634009 Tomsk, Russia
10 shared publications - Aleksey Yu. Dobrodeev
Научно-исследовательский институт онкологии, ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук
6 shared publications - Elena M. Slonimskaya
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634050 Tomsk, Russia
6 shared publications - Sergey G. Afanasyev
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
6 shared publications - Dmitry N. Kostromitsky
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences
5 shared publications
Latest Publications
- Open Access
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 5-14
Treatment outcomes in colorectal cancer patients with synchronous liver metastases
The purpose of the study was to analyze the 2-year survival rates in colorectal cancer (CRC) patients with synchronous liver metastases after combined modality treatment including perioperative chemotherapy.Material and Methods. A pilot prospective study included 30 colorectal cancer patients with initially resectable liver metastases, who received combined modality treatment including 3 courses of neoadjuvant chemotherapy with FOLFOXIRI in combination with cetuximab or bevacizumab (depending on the mutational status of the RAS family genes), radical surgery and 3 courses of adjuvant chemotherapy with FOLFOXIRI. The 2-year survival rates in colorectal cancer with synchronous liver metastases were analyzed on the basis of the main clinical and morphological characteristics of the tumor.Results. Within 2-years of follow-up, disease progression occurred in 7 (23.3 %) patients, including liver metastases in 4 (13.3 %) and multiple lung metastases in 3 (10 %) patients. There were no relapses in the area of intestinal and liver resection. One patient (3.3 %) died from disease progression. The 2-year recurrence-free and overall survival rates were 76.7 % and 96.7 %, respectively. The survival rate was significantly lower in patients with урТ4 primary tumor than in patients with урT3 tumor (44.4 % and 88.2 %, respectively, p=0.015). In patients without lymph node metastases ypN0, the survival rate was 100 %, and in patients with ypN2, the survival rate decreased to 50 % (p=0.016). The survival rate reached 94.1 % in patients with 1–3 liver metastases, and it was 50 % in patients with 7–11 metastases (p=0.02).Conclusion. Perioperative chemotherapy in CRC patients with initially resectable synchronous liver metastases provides encouraging 2-year survival rates, which are directly dependent on the extent of the tumor.
- 4 August 2025
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 24 (3) , 5-14
Open AccessTreatment outcomes in colorectal cancer patients with synchronous liver metastases
The purpose of the study was to analyze the 2-year survival rates in colorectal cancer (CRC) patients with synchronous liver metastases after combined modality treatment including perioperative chemotherapy.Material and Methods. A pilot prospective study included 30 colorectal cancer patients with initially resectable liver metastases, who received combined modality treatment including 3 courses of neoadjuvant chemotherapy with FOLFOXIRI in combination with cetuximab or bevacizumab (depending on the mutational status of the RAS family genes), radical surgery and 3 courses of adjuvant chemotherapy with FOLFOXIRI. The 2-year survival rates in colorectal cancer with synchronous liver metastases were analyzed on the basis of the main clinical and morphological characteristics of the tumor.Results. Within 2-years of follow-up, disease progression occurred in 7 (23.3 %) patients, including liver metastases in 4 (13.3 %) and multiple lung metastases in 3 (10 %) patients. There were no relapses in the area of intestinal and liver resection. One patient (3.3 %) died from disease progression. The 2-year recurrence-free and overall survival rates were 76.7 % and 96.7 %, respectively. The survival rate was significantly lower in patients with урТ4 primary tumor than in patients with урT3 tumor (44.4 % and 88.2 %, respectively, p=0.015). In patients without lymph node metastases ypN0, the survival rate was 100 %, and in patients with ypN2, the survival rate decreased to 50 % (p=0.016). The survival rate reached 94.1 % in patients with 1–3 liver metastases, and it was 50 % in patients with 7–11 metastases (p=0.02).Conclusion. Perioperative chemotherapy in CRC patients with initially resectable synchronous liver metastases provides encouraging 2-year survival rates, which are directly dependent on the extent of the tumor.
- Open Access
- 17 May 2025
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 24 (2) , 76-83
Early outcomes of preoperative chemotherapy combined with targeted therapy for rectal cancer
AIM: to assess early efficacy and tolerability of preoperative chemotherapy combined with targeted therapy in patients with rectal cancer (RC).PATIENTS AND METHODS: a pilot prospective study including 22 RC patients with KRAS wild-type gene is ongoing from 2021. There are 13 (59.1%) females and 9 (40.9%) males. Stage II RC was diagnosed in 2 (9.1%) patients and stage III RC in 20 (90.9%) patients. All patients received 6 cycles of mFOLFOX 6 chemotherapy combined with cetuximab targeted therapy followed by surgery. After completion of surgical treatment, patients with T4 and/or N + received adjuvant chemotherapy for 6 months (taking into account the time of preoperative treatment).RESULTS: the completion rate of preoperative treatment was 90.9%, and a 15% reduction in drug dosages was required in 9.1% of patients. Adverse events were observed in 45.4% of patients. Grade III toxicity was noted in 13.6% of patients (neutropenia in 9.1% and skin rash in 4.5%). The clinical and radiological response to preoperative chemo-targeted therapy was 77.3%, including complete (9.1%) and partial (68.2%) tumor regression. All patients underwent radical surgery. The rate of postoperative complications was 13.6%. Grade I and grade IIIa complications (according to Сlavien-Dindo classification) were observed in 9.1% and 4.5% of cases. Pathological complete response (pCR, according to Mandard TRG 1) was achieved in 13.6% of patients, and good pathological response (TRG 1-2) was observed in 31.8% of patients.CONCLUSION: preoperative chemotherapy combined with targeted therapy in RC patients with the wild type of the KRAS gene has a pronounced damaging effect on the tumor, and an acceptable toxicity profile does not affect intraand postoperative period. The short-term outcomes have been found to be encouraging. The study is ongoing to analyze the survival of patients.
- 17 May 2025
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 24 (2) , 76-83
Open AccessEarly outcomes of preoperative chemotherapy combined with targeted therapy for rectal cancer
AIM: to assess early efficacy and tolerability of preoperative chemotherapy combined with targeted therapy in patients with rectal cancer (RC).PATIENTS AND METHODS: a pilot prospective study including 22 RC patients with KRAS wild-type gene is ongoing from 2021. There are 13 (59.1%) females and 9 (40.9%) males. Stage II RC was diagnosed in 2 (9.1%) patients and stage III RC in 20 (90.9%) patients. All patients received 6 cycles of mFOLFOX 6 chemotherapy combined with cetuximab targeted therapy followed by surgery. After completion of surgical treatment, patients with T4 and/or N + received adjuvant chemotherapy for 6 months (taking into account the time of preoperative treatment).RESULTS: the completion rate of preoperative treatment was 90.9%, and a 15% reduction in drug dosages was required in 9.1% of patients. Adverse events were observed in 45.4% of patients. Grade III toxicity was noted in 13.6% of patients (neutropenia in 9.1% and skin rash in 4.5%). The clinical and radiological response to preoperative chemo-targeted therapy was 77.3%, including complete (9.1%) and partial (68.2%) tumor regression. All patients underwent radical surgery. The rate of postoperative complications was 13.6%. Grade I and grade IIIa complications (according to Сlavien-Dindo classification) were observed in 9.1% and 4.5% of cases. Pathological complete response (pCR, according to Mandard TRG 1) was achieved in 13.6% of patients, and good pathological response (TRG 1-2) was observed in 31.8% of patients.CONCLUSION: preoperative chemotherapy combined with targeted therapy in RC patients with the wild type of the KRAS gene has a pronounced damaging effect on the tumor, and an acceptable toxicity profile does not affect intraand postoperative period. The short-term outcomes have been found to be encouraging. The study is ongoing to analyze the survival of patients.
- Open Access
- 12 November 2024
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 23 (4) , 48-56
Impact of neoadjuvant chemotargeted therapy in patients with colorectal cancer and synchronous liver metastases in perioperative period
AIM: assess the impact of neoadjuvant chemotargeted therapy in patients with colorectal cancer and synchronous liver metastases in perioperative period.PATIENTS AND METHODS: a pilot prospective study included 30 patients with colorectal cancer and synchronous liver metastases (mCRC). The combined treatment included 3 cycles of neoadjuvant FOLFOXIRI chemotherapy with the addition of targeted agents: cetuximab (24 patients with wtKRAS) and bevacizumab (6 patients with mtKRAS) followed by radical surgery.RESULTS: the clinical and radiological response of colorectal cancer liver metastases to neoadjuvant chemotherapy (NACT) was complete in 4 (13.3%) patients and partial in 26 (86.7%) patients. Partial response to NACT in the primary tumor occurred in all patients. Adverse events of NACT were detected in 12 (40%) patients, 1 (3.3%) of them produced grade III toxicity. All patients underwent radical surgery (R0) 3–4 weeks after NACT, 28 (93.3%) of them underwent simultaneous colorectal and liver resection. Postoperative complications occurred in 21 (70%) patients, including grade I and grade IIIa complications (according to Сlavien-Dindo classification) — 22 (73.3%) and 2 (6.7%), respectively. Histology revealed pathologic complete response (pCR) of liver metastases in 1 (3.6%) case and pathological grade 3 regression of the primary tumor (TRG3, Mandard A.M.) in 23 (76.7%) patients. Two (6.7%) patients with complete clinical and radiological response of liver metastases, who did not undergo liver resection, had no evidence of disease progression 12 months after the treatment.CONCLUSION: in mCRC with synchronous liver metastases, NACT according to the FOLFOXIRI regimen in combination with targeted agents with a moderate toxicity profile provide significant carcinocidal effect without having a negative impact in the perioperative period. The study is ongoing to analyze 2-year disease-free and overall survival of patients.
- 12 November 2024
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 23 (4) , 48-56
Open AccessImpact of neoadjuvant chemotargeted therapy in patients with colorectal cancer and synchronous liver metastases in perioperative period
AIM: assess the impact of neoadjuvant chemotargeted therapy in patients with colorectal cancer and synchronous liver metastases in perioperative period.PATIENTS AND METHODS: a pilot prospective study included 30 patients with colorectal cancer and synchronous liver metastases (mCRC). The combined treatment included 3 cycles of neoadjuvant FOLFOXIRI chemotherapy with the addition of targeted agents: cetuximab (24 patients with wtKRAS) and bevacizumab (6 patients with mtKRAS) followed by radical surgery.RESULTS: the clinical and radiological response of colorectal cancer liver metastases to neoadjuvant chemotherapy (NACT) was complete in 4 (13.3%) patients and partial in 26 (86.7%) patients. Partial response to NACT in the primary tumor occurred in all patients. Adverse events of NACT were detected in 12 (40%) patients, 1 (3.3%) of them produced grade III toxicity. All patients underwent radical surgery (R0) 3–4 weeks after NACT, 28 (93.3%) of them underwent simultaneous colorectal and liver resection. Postoperative complications occurred in 21 (70%) patients, including grade I and grade IIIa complications (according to Сlavien-Dindo classification) — 22 (73.3%) and 2 (6.7%), respectively. Histology revealed pathologic complete response (pCR) of liver metastases in 1 (3.6%) case and pathological grade 3 regression of the primary tumor (TRG3, Mandard A.M.) in 23 (76.7%) patients. Two (6.7%) patients with complete clinical and radiological response of liver metastases, who did not undergo liver resection, had no evidence of disease progression 12 months after the treatment.CONCLUSION: in mCRC with synchronous liver metastases, NACT according to the FOLFOXIRI regimen in combination with targeted agents with a moderate toxicity profile provide significant carcinocidal effect without having a negative impact in the perioperative period. The study is ongoing to analyze 2-year disease-free and overall survival of patients.
- Open Access
- 23 March 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (1) , 162-169
Multimodal therapy for metastatic colorectal cancer: a case of complete clinical and radiological response of liver metastases
Background. Colorectal cancer is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Population-based studies have shown that 25–30 % of patients with colorectal cancer have synchronous liver metastases at the time of diagnosis. despite modern advances in oncology and surgery, only 25 % of patients with metastatic colorectal cancer (mCRC) are suitable for liver resection, which is the only curative treatment option for these patients. In recent years, the indications for curative treatment of mCRC have expanded. due to the introduction of new targeted drugs into clinical practice, the tumor response rate to preoperative therapy has increased, thus increasing surgical resection rate. Some patients experience a complete clinical response, which is defined as the complete disappearance of liver metastases. However, 30–70 % of patients develop recurrent metastases in the liver within the first year of follow-up, and currently, even in the presence of complete regression of metastases, it is recommended to perform resection of the initially affected hepatic segments. Case presentation. We describe a case of complete clinical and radiological response of liver metastases after chemotherapy in a patient with sigmoid colon cancer. Molecular genetic analysis revealed the wild type of the Kras, Nras and Braf genes. The patient received 3 courses of preoperative chemotherapy according to the FOLFOxIRI + Cetuximab regimen. Laparoscopic sigmoid colon resection with d3 lymph node dissection was followed by adjuvant chemotherapy with oxaliplatin and 5-fluorouracil (12 cycles). After 16 months of follow-up, no evidence of colon cancer recurrence and liver metastasis was found. Conclusion. Current targeted therapy has demonstrated efficacy in treating mCRC with synchronous liver metastases and makes it possible, in selected cases, to avoid the liver resection provided that a complete clinical and radiological response of the metastases is achieved.
- 23 March 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (1) , 162-169
Open AccessMultimodal therapy for metastatic colorectal cancer: a case of complete clinical and radiological response of liver metastases
Background. Colorectal cancer is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Population-based studies have shown that 25–30 % of patients with colorectal cancer have synchronous liver metastases at the time of diagnosis. despite modern advances in oncology and surgery, only 25 % of patients with metastatic colorectal cancer (mCRC) are suitable for liver resection, which is the only curative treatment option for these patients. In recent years, the indications for curative treatment of mCRC have expanded. due to the introduction of new targeted drugs into clinical practice, the tumor response rate to preoperative therapy has increased, thus increasing surgical resection rate. Some patients experience a complete clinical response, which is defined as the complete disappearance of liver metastases. However, 30–70 % of patients develop recurrent metastases in the liver within the first year of follow-up, and currently, even in the presence of complete regression of metastases, it is recommended to perform resection of the initially affected hepatic segments. Case presentation. We describe a case of complete clinical and radiological response of liver metastases after chemotherapy in a patient with sigmoid colon cancer. Molecular genetic analysis revealed the wild type of the Kras, Nras and Braf genes. The patient received 3 courses of preoperative chemotherapy according to the FOLFOxIRI + Cetuximab regimen. Laparoscopic sigmoid colon resection with d3 lymph node dissection was followed by adjuvant chemotherapy with oxaliplatin and 5-fluorouracil (12 cycles). After 16 months of follow-up, no evidence of colon cancer recurrence and liver metastasis was found. Conclusion. Current targeted therapy has demonstrated efficacy in treating mCRC with synchronous liver metastases and makes it possible, in selected cases, to avoid the liver resection provided that a complete clinical and radiological response of the metastases is achieved.
- Open Access
- 16 January 2024
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 18 (1) , 4-7
Long-term response with the atypical reaction to nivolumab in microsatellite stability metastatic colorectal cancer: A case report
Immunotherapy has become an integral part of a comprehensive treatment approach to metastatic colorectal cancer (mCRC). Nivolumab (Opdivo) is a human immunoglobulin G4 monoclonal antibody that blocks the interaction between the programmed cell death 1 (PD-1) receptor and its ligands 1/2 (PD-L1/PD-L2), leading to inhibition of T-cell proliferation, cytokine secretion, and enhanced immune response. The US Food and Drug Administration (FDA) has approved this drug for use in high microsatellite instability (MSI-high)/deficiencies in mismatch repair (dMMR) advanced CRC patients. However, its efficacy is extremely limited in microsatellite stability (MSS)/mismatch repair proficient (pMMR) patients. We report a case of a 42-year-old man diagnosed with MSS/pMMR mCRC who has achieved a durable response to nivolumab after a progression under chemotherapy with antiangiogenic treatment. We observed for the first time an atypical response after 8 months of nivolumab treatment, with the regression of previous primary pulmonary lesions and the presence of new para-aortic lymph node lesions. This report demonstrates that a subset of pretreated mCRC patients with the MSS/pMMR phenotype may benefit from nivolumab and these patients need more attention.
- 16 January 2024
- Published by Aboutscience Srl in Drug Target Insights
- Vol. 18 (1) , 4-7
Open AccessLong-term response with the atypical reaction to nivolumab in microsatellite stability metastatic colorectal cancer: A case report
Immunotherapy has become an integral part of a comprehensive treatment approach to metastatic colorectal cancer (mCRC). Nivolumab (Opdivo) is a human immunoglobulin G4 monoclonal antibody that blocks the interaction between the programmed cell death 1 (PD-1) receptor and its ligands 1/2 (PD-L1/PD-L2), leading to inhibition of T-cell proliferation, cytokine secretion, and enhanced immune response. The US Food and Drug Administration (FDA) has approved this drug for use in high microsatellite instability (MSI-high)/deficiencies in mismatch repair (dMMR) advanced CRC patients. However, its efficacy is extremely limited in microsatellite stability (MSS)/mismatch repair proficient (pMMR) patients. We report a case of a 42-year-old man diagnosed with MSS/pMMR mCRC who has achieved a durable response to nivolumab after a progression under chemotherapy with antiangiogenic treatment. We observed for the first time an atypical response after 8 months of nivolumab treatment, with the regression of previous primary pulmonary lesions and the presence of new para-aortic lymph node lesions. This report demonstrates that a subset of pretreated mCRC patients with the MSS/pMMR phenotype may benefit from nivolumab and these patients need more attention.
- Open Access
- 15 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 76-85
Non-structural role of cytokeratins in malignant neoplasms
Cytokeratins (CKs) are well studied as intermediate filaments of the cytoskeleton of epithelial cells, providing specific cell structure and morphology, in particular, apico-basal cell polarization. Meanwhile, a certain specificity of the association of CK with different types of epithelia is noted. CK heterogeneity in the glandular epithelium is particularly pronounced and is associated with anatomical localization. The relative specificity of CKs in epithelium of different localization is preserved to a great extent in carcinomas originating from this epithelium as well. Due to this fact the determination of CK spectrum in tumor cells is quite an effective tool for nosological diagnostics of carcinomas. however, the function of CKs is not limited to providing the cell structure. The presence and amount of CK changes during the most important processes in normal and tumor cells: movement/invasion, apoptosis, proliferation, epithelial-mesenchymal plasticity.A question arises: Is initiation of the above-listed processes happens first, and therefore CK changes are secondary and «passive», or in some processes CK changes can play a role of a trigger? Knowing the answer to this question is not only of fundamental importance, but is also important for finding ways to control the above processes by influencing the CKs.
- 15 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 76-85
Open AccessNon-structural role of cytokeratins in malignant neoplasms
Cytokeratins (CKs) are well studied as intermediate filaments of the cytoskeleton of epithelial cells, providing specific cell structure and morphology, in particular, apico-basal cell polarization. Meanwhile, a certain specificity of the association of CK with different types of epithelia is noted. CK heterogeneity in the glandular epithelium is particularly pronounced and is associated with anatomical localization. The relative specificity of CKs in epithelium of different localization is preserved to a great extent in carcinomas originating from this epithelium as well. Due to this fact the determination of CK spectrum in tumor cells is quite an effective tool for nosological diagnostics of carcinomas. however, the function of CKs is not limited to providing the cell structure. The presence and amount of CK changes during the most important processes in normal and tumor cells: movement/invasion, apoptosis, proliferation, epithelial-mesenchymal plasticity.A question arises: Is initiation of the above-listed processes happens first, and therefore CK changes are secondary and «passive», or in some processes CK changes can play a role of a trigger? Knowing the answer to this question is not only of fundamental importance, but is also important for finding ways to control the above processes by influencing the CKs.
- Open Access
- 15 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 47-60
Integration of phosphoinositide 3-kinase (PI3K) and transforming growth factor β1 (TGF-β1) signaling cascades: role in the therapeutic inefficiency of tamoxifen
Growth factors signaling cascades and their interaction with the central regulatory targets of tumor cells and estrogens are considered as the main mechanisms of hormonal resistance in breast cancer. The integration of the transforming growth factor β1 (TGF-β1) and PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B)/mTOR (mammalian target of rapamycin) signaling pathway may result in the activation of proliferation and, as a result, the development of an in-effective response to therapy and disease progression. The review summarizes a systematic analysis of the literature data on the role of TGF-β1 signaling in the mechanisms of tamoxifen resistance to in the aspect of interaction with the PI3K/Akt/mTOR. The interaction between the estrogen receptors α signaling and tamoxifen, the mechanisms of regulatory activation of TGF-β1 and PI3K/Akt/mTOR, as well as their contribution to the tamoxifen response are considered. The direct involvement of TGF-β1/PI3K in the mechanisms of tamoxifen resistance to determines the prospects for studying the effector of these cascades as molecular targets. The knowledge accumulated to date allows considering the TGF-β1/PI3K signaling pathway as a potential molecular tool for the search for effective strategies for blocking the resistance of tumor cells to tamoxifen.
- 15 December 2023
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 10 (4) , 47-60
Open AccessIntegration of phosphoinositide 3-kinase (PI3K) and transforming growth factor β1 (TGF-β1) signaling cascades: role in the therapeutic inefficiency of tamoxifen
Growth factors signaling cascades and their interaction with the central regulatory targets of tumor cells and estrogens are considered as the main mechanisms of hormonal resistance in breast cancer. The integration of the transforming growth factor β1 (TGF-β1) and PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B)/mTOR (mammalian target of rapamycin) signaling pathway may result in the activation of proliferation and, as a result, the development of an in-effective response to therapy and disease progression. The review summarizes a systematic analysis of the literature data on the role of TGF-β1 signaling in the mechanisms of tamoxifen resistance to in the aspect of interaction with the PI3K/Akt/mTOR. The interaction between the estrogen receptors α signaling and tamoxifen, the mechanisms of regulatory activation of TGF-β1 and PI3K/Akt/mTOR, as well as their contribution to the tamoxifen response are considered. The direct involvement of TGF-β1/PI3K in the mechanisms of tamoxifen resistance to determines the prospects for studying the effector of these cascades as molecular targets. The knowledge accumulated to date allows considering the TGF-β1/PI3K signaling pathway as a potential molecular tool for the search for effective strategies for blocking the resistance of tumor cells to tamoxifen.
- Open Access
- 31 October 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (5) , 135-141
Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
Aim of the study: a systematic analysis of the modern literature data on the nivolumab monotherapy efficacy in patients with metastatic colorectal cancer (mCRC). Material and methods. The review summarizes the results of clinical studies of the nivolumab efficacy in patients with mCRC between 2012 and 2022. The current approaches to assessing the tumor response in patients treated with immune checkpoint inhibitors are considered, including response patterns and criteria. Results. Data analysis showed that the use of nivolumab in mCRC patients had significant clinical benefits. Nivolumab monotherapy was shown to improve survival in patients with high microsatellite instability (MSI) or deficiencies in mismatch repair (dMMR) that progressed during standard chemotherapy. Numerous clinical studies indicate the atypical response to nivolumab. Traditional response criteria, such as RECIST do not always adequately assess the therapeutic efficacy of nivolumab in patients with mCRC. Conclusion. To improve the efficacy of mCRC treatment, standardized approaches based on the proposed specific criteria for response to immunotherapy, including immune related RECIST, immune RECIST, and immune-modified RECIST must be developed.
- 31 October 2022
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (5) , 135-141
Open AccessNivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
Aim of the study: a systematic analysis of the modern literature data on the nivolumab monotherapy efficacy in patients with metastatic colorectal cancer (mCRC). Material and methods. The review summarizes the results of clinical studies of the nivolumab efficacy in patients with mCRC between 2012 and 2022. The current approaches to assessing the tumor response in patients treated with immune checkpoint inhibitors are considered, including response patterns and criteria. Results. Data analysis showed that the use of nivolumab in mCRC patients had significant clinical benefits. Nivolumab monotherapy was shown to improve survival in patients with high microsatellite instability (MSI) or deficiencies in mismatch repair (dMMR) that progressed during standard chemotherapy. Numerous clinical studies indicate the atypical response to nivolumab. Traditional response criteria, such as RECIST do not always adequately assess the therapeutic efficacy of nivolumab in patients with mCRC. Conclusion. To improve the efficacy of mCRC treatment, standardized approaches based on the proposed specific criteria for response to immunotherapy, including immune related RECIST, immune RECIST, and immune-modified RECIST must be developed.
- 1 December 2021
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 62, 62-69
Role of TGF-β signaling in the mechanisms of tamoxifen resistance
- 1 December 2021
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 62, 62-69
Role of TGF-β signaling in the mechanisms of tamoxifen resistance
- Open Access
- 7 April 2021
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 20 (1) , 16-23
PI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN
The PI3K/Akt/mTOR is a key signaling system that binds oncogenes and various receptors to many cell functions, promotes estrogen resistance, and is the most frequently activated signaling pathway in malignant neoplasm, including breast cancer (BC). About 70 % of BC is hormone‑receptor positive and the endocrine therapy is the main component of treatment for hormone‑receptor positive BC patients. Tamoxifen remains one of the basic drugs for adjuvant endocrine therapy in estrogen‑positive BC patients. However, due to acquired resistance to this drug, 25–30 % of patients develop a relapse or disease progression. Resistance to tamoxifen is one of the key clinical problems in the treatment of estrogen‑positive BC. The potential mechanisms of tamoxifen resistance may be associated with crosstalk between estrogen receptors and PI3K/Akt/mTOR signaling. This review summarizes the current literature data on the role of the PI3K/Akt/mTOR signaling pathway in the mechanisms of hormonal resistance, including a complete characterization of its main components and the features of PI3K/Akt/mTOR interaction with estrogen receptors. The results of studies of the main components of the cascade as molecular markers of response to tamoxifen therapy in estrogen‑positive BC patients are presented. Further study of the PI3K/Akt/mTOR crosstalk with various signaling pathways will contribute to both the understanding of carcino‑ genesis and the development of new molecular‑targeted anticancer drugs for the treatment of tamoxifen‑ resistant breast tumors.
- 7 April 2021
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 20 (1) , 16-23
Open AccessPI3K/AKT/MTOR: CONTRIBUTION TO THE TUMOR PHENOTYPE SENSITIVE TO TAMOXIFEN
The PI3K/Akt/mTOR is a key signaling system that binds oncogenes and various receptors to many cell functions, promotes estrogen resistance, and is the most frequently activated signaling pathway in malignant neoplasm, including breast cancer (BC). About 70 % of BC is hormone‑receptor positive and the endocrine therapy is the main component of treatment for hormone‑receptor positive BC patients. Tamoxifen remains one of the basic drugs for adjuvant endocrine therapy in estrogen‑positive BC patients. However, due to acquired resistance to this drug, 25–30 % of patients develop a relapse or disease progression. Resistance to tamoxifen is one of the key clinical problems in the treatment of estrogen‑positive BC. The potential mechanisms of tamoxifen resistance may be associated with crosstalk between estrogen receptors and PI3K/Akt/mTOR signaling. This review summarizes the current literature data on the role of the PI3K/Akt/mTOR signaling pathway in the mechanisms of hormonal resistance, including a complete characterization of its main components and the features of PI3K/Akt/mTOR interaction with estrogen receptors. The results of studies of the main components of the cascade as molecular markers of response to tamoxifen therapy in estrogen‑positive BC patients are presented. Further study of the PI3K/Akt/mTOR crosstalk with various signaling pathways will contribute to both the understanding of carcino‑ genesis and the development of new molecular‑targeted anticancer drugs for the treatment of tamoxifen‑ resistant breast tumors.